4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 112 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $57,018 | -35.9% | 4,479 | -9.0% | 0.04% | -34.0% |
Q2 2023 | $88,959 | +25.0% | 4,923 | +18.9% | 0.05% | +35.9% |
Q1 2023 | $71,167 | -44.1% | 4,140 | -27.8% | 0.04% | -40.9% |
Q4 2022 | $127,286 | +9.7% | 5,731 | -25.4% | 0.07% | +26.9% |
Q1 2022 | $116,000 | -35.2% | 7,683 | -5.6% | 0.05% | -23.5% |
Q4 2021 | $179,000 | -8.7% | 8,140 | +12.2% | 0.07% | -20.9% |
Q3 2021 | $196,000 | +6.5% | 7,257 | -5.0% | 0.09% | +13.2% |
Q2 2021 | $184,000 | – | 7,642 | – | 0.08% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Octagon Capital Advisors LP | 831,267 | $22,419,000 | 5.52% |
Aquilo Capital Management, LLC | 1,099,944 | $29,665,000 | 5.39% |
BVF INC/IL | 2,005,862 | $54,098,000 | 2.11% |
Casdin Capital, LLC | 1,115,455 | $30,084,000 | 0.75% |
Soleus Capital Management, L.P. | 120,900 | $3,261,000 | 0.51% |
Eagle Health Investments LP | 57,090 | $1,540,000 | 0.49% |
Centiva Capital, LP | 358,863 | $7,220,000 | 0.45% |
VIKING GLOBAL INVESTORS LP | 3,937,914 | $106,206,000 | 0.29% |
ArrowMark Colorado Holdings LLC | 1,003,447 | $27,063,000 | 0.21% |
Perceptive Advisors | 375,256 | $10,121,000 | 0.15% |